These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1821649)

  • 1. Antisense technology: commercial implications.
    Hawkins JW
    Antisense Res Dev; 1991; 1(3):283-4. PubMed ID: 1821649
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antisense oligonucleotides--a new generation of potential drugs].
    Moser HE
    Praxis (Bern 1994); 1995 Sep; 84(38):1055-6. PubMed ID: 7481305
    [No Abstract]   [Full Text] [Related]  

  • 3. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biotechnologic drugs and chemotherapy for infectious diseases].
    Honorato J
    Rev Esp Quimioter; 2007 Sep; 20(3):310-6. PubMed ID: 18080027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides in the design of new therapeutic strategies.
    Piulats J; Tarrasón G
    Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():31-2. PubMed ID: 9403853
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress in antisense technology: the end of the beginning.
    Crooke ST
    Methods Enzymol; 2000; 313():3-45. PubMed ID: 10595347
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic potential of antisense nucleic acid molecules.
    Opalinska JB; Gewirtz AM
    Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotechnology and drug discovery--the future is here: a guide for the practicing urologist.
    Avidor Y; Mabjeesh NJ; Pimenta I; Matzkin H
    Urology; 2002 May; 59(5):643-51. PubMed ID: 11992833
    [No Abstract]   [Full Text] [Related]  

  • 10. Keeping the biotechnology of antisense in context.
    Stein CA
    Nat Biotechnol; 1999 Mar; 17(3):209. PubMed ID: 10096271
    [No Abstract]   [Full Text] [Related]  

  • 11. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense technology--commercialization of new biotherapeutics.
    Conway BJ; Chrisey LA
    Antisense Res Dev; 1991; 1(2):195-9. PubMed ID: 1841661
    [No Abstract]   [Full Text] [Related]  

  • 13. Sense and antisense for investors.
    Jacobs T
    Nat Biotechnol; 2002 Jun; 20(6):543. PubMed ID: 12042846
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development of antisense nucleotides for therapy].
    Wang J; Wang L; Wang Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Feb; 23(1):230-4. PubMed ID: 16532848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antisense constructs, therapeutics of the future?].
    Van Aerschot A
    Verh K Acad Geneeskd Belg; 2000; 62(6):565-601. PubMed ID: 11196580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of capillary electrophoresis in biotechnology.
    Lagu AL
    Electrophoresis; 1999 Oct; 20(15-16):3145-55. PubMed ID: 10596822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gene technology and current possibilities for pharmacological intervention].
    Pelkonen O
    Duodecim; 1992; 108(15):1299-300. PubMed ID: 1366088
    [No Abstract]   [Full Text] [Related]  

  • 18. Making sense of antisense and interference.
    Morrow T
    Manag Care; 2003 Nov; 12(11):62-3. PubMed ID: 14666589
    [No Abstract]   [Full Text] [Related]  

  • 19. Oligonucleotides--from design to the clinic.
    Bennett CF
    Curr Opin Mol Ther; 1999 Jun; 1(3):296. PubMed ID: 11713793
    [No Abstract]   [Full Text] [Related]  

  • 20. Antisense oligonucleotides for haematological malignancies.
    Cotter FE
    Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.